Pharma News

Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer

  • Posted on: 21 September 2020
  • By: PharmaTutor News

Roche announced that it presented the latest results from three Phase III studies from the Tecentriq® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Pages